News

Transpharmation’s CEO Mark Duxon was pleased to speak with Guy Martin of The Pharma Letter about the impact of #Brexit on CROs. We have opened our fourth lab, most recently in Poland, and now with a footprint in the UK and continental Europe we are able to extend our services and partnerships to mitigate against border pressures, optimising opportunities for innovation and exciting collaborations.

Read the full interview here

Transpharmation announces the opening of a new laboratory in Poland. “We see Poland rising within the biotechnology and drug-discovery sector, with pharmaceutical companies moving and expanding to develop new technologies and focus on novel treatments to tackle neurodegenerative, neuropsychiatric and neurodevelopmental diseases which affect us all,” reveals Mark Duxon CEO. This news comes not long after Transpharmation revealed the launch of additional laboratory space at Discovery Park, Kent, boosting its growing list of facilities and opening up further opportunities to expand its preclinical services.

Read the full press release here

The creation of Transpharmation Poland will also create new jobs and new career options. In the first instance, Transpharmation is seeking a senior scientist and a research assistant, establishing the laboratory as its primary centre for neuropsychiatric disorders. If you have a background in preclinical neuroscience, are eligible to work in Poland and would like to be a part of this significant new venture please contact Dr. Ewa Sokolowska This email address is being protected from spambots. You need JavaScript enabled to view it.

Senior Scientist / Scientist

Technician Research Assistance

Frontiers in Psychiatry have just published a peer review journal by the Transpharmation Ireland team, led by Jack Prenderville. ‘The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.’ Major depressive disorder, (MDD) is the leading cause of disability worldwide. The majority of antidepressant drugs require several weeks or months of treatment to demonstrate efficacy and a subset of patients are resistant to such interventions. In this publication we examine depressive-like behavioural phenotypes in the Wistar-Kyoto rat model of depression, establish and demonstrate an effective clinically relevant dose of the novel therapeutic agent ketamine. To read the full publication please head to https://www.frontiersin.org/articles/10.3389/fpsyt.2020.599588/full

Recognised by drug developers world-wide, Transpharmation’s client base continues to grow. With the expansion of therapeutic indications offered, the move to new, state of the art research facilities at Discovery Park in Kent is perfectly timed to hit the ground running from January 2021. With a vast array of laboratory and office space, managed by the hugely experienced company Agenda Life Sciences, Transpharmation’s scientists will have everything they need in place to deliver scientific excellence, remaining focussed on the important drug discovery work we carry out for our clients. 

Discovery Park, home to many specialist research companies, was recently named a Life Sciences Opportunity Zone by the UK Government’s Offices for Life Sciences. This multi-million pound site is known for its heritage of scientific excellence and delivery of new treatments for patients. With strong transport links to
airports, trains and ports it is ideally positioned for Transpharmation’s growing global customer portfolio.

Whilst Transpharmation will retain their facilities at The London Bioscience Innovation Centre, Royal Veterinary College and Trinity College Institute of Neuroscience, Dublin, the move to Discovery Park, on their 10th year anniversary, is a pivotal point in the company’s history and sets the agenda for their future growth.

Official press release

Ten years has gone by so quickly. When the company started, we limited ourselves to the study of pain and cognition. Now we offer specialist bespoke studies across multiple therapeutic indications including pain, depression, schizophrenia, epilepsy and neurodegeneration to clients all around the world. Science will always remain our passion, along with the drive to research and deliver life-changing medicines. Thank you very much for your support along the way, we hope to work with you for many years to come.

Transpharmation Ltd are delighted to be one of the sponsors of the first virtual conference held by The International Association for the Study of Pain, (IASP). The event runs from 8th September 2020 to 31st March 2021. We’ll be showcasing our latest specialist poster; ‘The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type 1 diabetic rodents’. Come and see us! #iaspvirtualseries https://www.eventscribe.com/2020/IASP-Virtual-Series-on-Pain/

We're pleased to share with you the newly launched website for the BIND project and we're delighted to be a part of the scientific team. https://bindproject.eu/ It's the first project of this scale to improve characterisation of brain involvement in Duchenne and Becker Muscular Dystrophy (DMD and BMD). This EU-funded project, connecting 19 partners from Europe and Japan, aims to address a crucial aspect of DMD and BMD that was already recognised in 1861, when Duchenne de Boulogne first described the neuromuscular condition. In the last few decades however, most of the efforts have focused on improving outcomes related to muscle weakness, whilst brain involvement has received less attention.

Congratulations to Dr. Jack Prenderville, Head of Research at Transpharmation's Irish site, on his nomination to the position of Adjunct Assistant Professor in the Department of Physiology at Trinity College Dublin. For a number of years Jack has made a valuable contribution to teaching and research, delivering neuropharmacology lectures and supervising undergraduate research students within the Department. This recognition is well deserved and adds an additional dimension to his role within Transpharmation.

We are pleased to announce an enterprise partnership with Professor Andrew Harkin, Trinity College Institute of neuroscience (TCIN) co-funded by Irish research Council (IRC) and Transpharmation Ltd. This partnership, initially supported for a four-year period, will establish a clinically relevant experimental platform to facilitate the development of new therapeutics for the treatment of Parkinson’s disease.

Read more ...

During these unprecedented times, good communication and maintaining contact is more important than ever. That's why at Transpharmation we're making use of all the resources available for holding regular meetings with our clients to discuss ongoing and future projects. Although some of us are working from home and juggling family commitments, we remain close to you. We're all in this together and it's nice to stay in touch.

Contact me at any time: This email address is being protected from spambots. You need JavaScript enabled to view it.

Business Continuation

Business Continuation

Pharma Tech Outlook magazine have named Transpharmation ‘company of the year’ in their ‘top 5 UK CRO’s’ feature. We’re proud of this achievement on behalf of all the clients that we’ve worked with over the years and it’s a great start to our 10th anniversary year.

Read more ...

We are delighted to announce that Transpharmation Ltd is to be one of the partners enlisted in the EU-funded first international project to study dystrophin in the brain in Duchenne and Becker Muscular Dystrophy (DMD and BMD).

Read more ...